Neuberger Berman Group
NVCR icon

Neuberger Berman Group’s NovoCure NVCR Stock Holding History

Neuberger Berman Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,444
Closed -$414K – 1848
2022
Q3 		$414K Buy
5,444
+2,062
+61% +$161K ﹤0.01% 1520
2022
Q2 		$235K Sell
3,382
-3,801
-53% -$286K ﹤0.01% 1717
2022
Q1 		$595K Buy
+7,183
New +$529K ﹤0.01% 1493
2020
Q2 		– Sell
-21,000
Closed -$1.41M – 1583
2020
Q1 		$1.41M Buy
+21,000
New +$1.66M ﹤0.01% 1022

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group's NVCR Position: Q4 2022 in Review

Neuberger Berman Group sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 5,444 shares — an estimated $414K sold.

Neuberger Berman Group first reported a position in NVCR in Q1 2020 and held it in 4 quarters. The position peaked at $1.41M in Q1 2020. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

  • Neuberger Berman Group reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
  • Neuberger Berman Group sold 5,444 NovoCure shares in Q4 2022, an estimated $414K.
  • Neuberger Berman Group first reported a position in NovoCure in Q1 2020 and held it in 4 quarters.
  • Neuberger Berman Group's NovoCure position peaked at $1.41M in Q1 2020.
  • 304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Neuberger Berman Group's 13F filing for Q4 2022, filed 13 Feb 2023.